Medivation has 'best-in-class' ambitions for newly purchased PARP inhibitor

Medivation ($MDVN) made a name for itself with Xtandi, the prostate cancer med that's now giving Johnson & Johnson's ($JNJ) Zytiga a run for its money. Now, it wants to challenge other drugmakers in the PARP inhibitor field, too. And as analysts point out, Medivation thinks the PARP med it picked up from BioMarin ($BMRN) this week could be a "best-in-class" performer. Report

Suggested Articles

Former Indivior CEO Shaun Thaxter will face six months in federal prison for his role in misleading government officials on the dangers of Suboxone.

As of Friday after local time, 36 people have died in Korea after getting flu shots provided by at least seven companies, including Sanofi.

Two prominent pneumococcal vaccines from Merck and Pfizer are running low in Europe in a possible ill omen for the coming winter: report.